Arriving in the arena of obesity management, retatrutide presents a different method. Unlike many available medications, retatrutide functions as a double agonist, concurrently targeting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) receptors. This dual stimulation promotes various advantageous effects, lik